Document:

ex-10.68

   
 LOAN AGREEMENT
 April 13, 2020
  
 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$55,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on April 13, 2020.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from April 13, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Longview Investment Limited
	 Cell MedX Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ Rick Donaldson
	 /s/  Yanika Silina

	 Name: Rick Donaldson
	 Yanika Silina, CFO

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$55,000
	 April 13, 2020

  
  
 FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Longview Investment Limited (the “Lender”) the sum of $55,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from April 13, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum  when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
  
  
 BORROWER
 Cell MedX Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, CFOex-10.69

  LOAN AGREEMENT
  
 THIS LOAN AGREEMENT (this "Agreement") dated this 3rd day of July, 2020
  
 BETWEEN:
  
 David M. Jeffs of 2615 15th Avenue West, Vancouver, BC  V6K 2Z6, Canada
 (the "Lender")
  
 OF THE FIRST PART
  
 AND
 Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA
 (the "Borrower")
  
 OF THE SECOND PART
  
 IN CONSIDERATION OF the Lender loaning certain monies (the "Loan") to the Borrower, and the Borrower repaying the Loan to the Lender, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
  
 Loan Amount & Interest
  
 The Lender promises to loan twenty thousand ($20,000.00) CAD, to the Borrower and the Borrower promises to repay this principal amount to the Lender, at such address as may be provided in writing, with interest calculated and compounded monthly on the unpaid principal at the rate of 6.0% per annum.
  
 Payment
 This Loan will be repaid in full from the first proceeds the Borrower receives through the exercise of any existing warrants currently outstanding for the purchase of the Borrower’s common shares or One (1) year from the execution of this Agreement, whichever event arrives soonest.
  
 At any time while not in default under this Agreement, the Borrower may pay the outstanding balance then owing under this Agreement to the Lender without further bonus or penalty.
  
 Default
 Notwithstanding anything to the contrary in this Agreement, if the Borrower defaults in the performance of any obligation under this Agreement, then the Lender may declare the principal amount owing and interest due under this Agreement at that time to be immediately due and payable.
  
 Governing Law
 This Agreement will be construed in accordance with and governed by the laws of the Province of British Columbia.
 
 
 Costs
 All costs, expenses and expenditures including, without limitation, the complete legal costs incurred by enforcing this Agreement as a result of any default by the Borrower, will be added to the principal then outstanding and will immediately be paid by the Borrower.
  
 Binding Effect
 This Agreement will pass to the benefit of and be binding upon the respective heirs, executors, administrators, successors and permitted assigns of the Borrower and Lender. The Borrower waives presentment for payment, notice of non-payment, protest, and notice of protest.
  
 Amendments
 This Agreement may only be amended or modified by a written instrument executed by both the Borrower and the Lender.
  
 Severability
 The clauses and paragraphs contained in this Agreement are intended to be read and construed independently of each other. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, it is the parties' intent that such provision be reduced in scope by the court only to the extent deemed necessary by that court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected, impaired or invalidated as a result.
  
 General Provisions
 Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.
  
 Entire Agreement
 This Agreement constitutes the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 IN WITNESS WHEREOF, the parties have duly affixed their signatures under hand and seal on this 3rd day of July, 2020.
  
  
 	 SIGNED, SEALED, AND DELIVERED
 this 9th day of July, 2020 in front of the person below who is over 18 years of age.
  
 _/s/ Heidi Henderson
 (signature of witness)
  
 WITNESS DETAILS:
 Name:
 Heidi Henderson
  
 Address:
 _______________
  
  
 Vancouver, BC
  
  
	  
	  
  
  
 /s/ David Jeffs
 David M. Jeffs
  
  
  
  
  

  
  
  
  
 	 SIGNED, SEALED, AND DELIVERED
 this 9th day of July, 2020 in front of the person below who is over 18 years of age.
  
 /s/ Greg Ball
 (signature of witness)
  
 WITNESS DETAILS:
 Name:
 Greg Ball
  
 Address:
 _______________
  
  
 Vancouver, BC
  
  
	  
	  
 Cell MedX Corp.
  
  
 per: /s/ Joao da Costa
 Joao (John) da Costaex-10.70

   
 LOAN AGREEMENT
 August 31, 2020
  
 Tradex Capital Corp., (the “Lender”) with an address at 1177 W. Hastings Street, Suite 2288, Vancouver, BC V6E 2K3, advanced USD$65,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on August 31, 2020.
  
 The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from August 31, 2020 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
  
 The Borrower acknowledges that at any time, the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest (together the “Convertible Amount”) into restricted units of common stock in the capital of the Borrower. The Convertible Amount will be converted into fully paid, non-assessable and, subject to the United States securities laws, restricted units of common stock in the capital of the Borrower on the terms and at a conversion price of the then current private placement offering.
  
 The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
  
 	 LENDER
	 BORROWER

	 Tradex Capital Corp.
	 Cell MedX Corp.

	  
	  

	 Per:
	 Per:

	  
	  

	  
	  

	 /s/ William Friesen
	 /s/  Yanika Silina

	 Name: Rick Donaldson
	 Yanika Silina, CFO

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
 
  
 PROMISSORY NOTE
  
 	 Principal Amount: USD$65,000
	 August 31, 2020

  
  
 FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Tradex Capital Corp., (the “Lender”) the sum of $65,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from August 31, 2020 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
  
 For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum  when the Principal Sum is repaid.
  
 The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
  
 Any time prior to this Promissory Note being repaid the Lender may, in its sole discretion, provide the Borrower with written instructions to convert any payment of Principal Sum, and/or Interest into restricted units of common stock in the capital of the Borrower. Payments will be converted into fully paid, non-assessable and, subject to United States securities laws, restricted units of common stock in the capital of the Borrower (the “Conversion Units”) on the terms and at a conversion price of the then current private placement offering.
  
 The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
  
  
 BORROWER
 Cell MedX Corp.
  
 Per:
  
  
 /s/ Yanika Silina
 Yanika Silina, CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]